Taken together, PIP5K1α inhibition, either by ISA-2011B or siRNA-mediated knockdown, significantly abrogated the activity of ERα and estrogen on inducing the target genes, suggesting a potential of ISA-2011B for targeting ER+ breast cancer with elevated PIP5K1α expression. The gene discussed is ESR1; the disease is breast cancer.